SI2625175T1 - Kristaliničen (r)-(e)-2-(4-(2-(5-(1-(3,5-dikloropiridin-4-il)etoksi)- 1h-indazol-3-il)vinil-1h-pirazol-1-il)etanol in njegova uporaba kot inhibitor fgfr - Google Patents

Kristaliničen (r)-(e)-2-(4-(2-(5-(1-(3,5-dikloropiridin-4-il)etoksi)- 1h-indazol-3-il)vinil-1h-pirazol-1-il)etanol in njegova uporaba kot inhibitor fgfr

Info

Publication number
SI2625175T1
SI2625175T1 SI201130673T SI201130673T SI2625175T1 SI 2625175 T1 SI2625175 T1 SI 2625175T1 SI 201130673 T SI201130673 T SI 201130673T SI 201130673 T SI201130673 T SI 201130673T SI 2625175 T1 SI2625175 T1 SI 2625175T1
Authority
SI
Slovenia
Prior art keywords
dichloropyridin
indazol
pyrazol
ethoxy
crystalline
Prior art date
Application number
SI201130673T
Other languages
English (en)
Inventor
Benjamin Alan Diseroad
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2625175(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2625175T1 publication Critical patent/SI2625175T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201130673T 2010-10-05 2011-09-29 Kristaliničen (r)-(e)-2-(4-(2-(5-(1-(3,5-dikloropiridin-4-il)etoksi)- 1h-indazol-3-il)vinil-1h-pirazol-1-il)etanol in njegova uporaba kot inhibitor fgfr SI2625175T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38991110P 2010-10-05 2010-10-05
EP11771312.3A EP2625175B1 (en) 2010-10-05 2011-09-29 Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol and its use as fgfr inhibitor
PCT/US2011/053798 WO2012047699A1 (en) 2010-10-05 2011-09-29 Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor

Publications (1)

Publication Number Publication Date
SI2625175T1 true SI2625175T1 (sl) 2016-01-29

Family

ID=44999860

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130673T SI2625175T1 (sl) 2010-10-05 2011-09-29 Kristaliničen (r)-(e)-2-(4-(2-(5-(1-(3,5-dikloropiridin-4-il)etoksi)- 1h-indazol-3-il)vinil-1h-pirazol-1-il)etanol in njegova uporaba kot inhibitor fgfr

Country Status (35)

Country Link
US (1) US8530665B2 (sl)
EP (1) EP2625175B1 (sl)
JP (1) JP5940547B2 (sl)
KR (1) KR101527661B1 (sl)
CN (1) CN103153983B (sl)
AR (1) AR083091A1 (sl)
AU (1) AU2011312485B2 (sl)
BR (1) BR112013006336A2 (sl)
CA (1) CA2813329C (sl)
CL (1) CL2013000884A1 (sl)
CO (1) CO6710911A2 (sl)
DK (1) DK2625175T3 (sl)
DO (1) DOP2013000072A (sl)
EA (1) EA021817B1 (sl)
EC (1) ECSP13012539A (sl)
ES (1) ES2558777T3 (sl)
HK (1) HK1184147A1 (sl)
HR (1) HRP20151299T1 (sl)
HU (1) HUE026379T2 (sl)
IL (1) IL224850A (sl)
JO (1) JO3062B1 (sl)
MA (1) MA34552B1 (sl)
ME (1) ME02307B (sl)
MX (1) MX2013003907A (sl)
NZ (1) NZ608482A (sl)
PE (1) PE20140252A1 (sl)
PL (1) PL2625175T3 (sl)
PT (1) PT2625175E (sl)
RS (1) RS54457B1 (sl)
SG (1) SG188286A1 (sl)
SI (1) SI2625175T1 (sl)
TW (1) TWI418554B (sl)
UA (1) UA111725C2 (sl)
WO (1) WO2012047699A1 (sl)
ZA (1) ZA201301560B (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111705099B (zh) * 2020-07-01 2022-03-08 天津药明康德新药开发有限公司 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法
MX2023007162A (es) * 2020-12-17 2023-06-29 Blossomhill Therapeutics Inc Macrociclos y sus usos.
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002022598A1 (en) * 2000-09-11 2002-03-21 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
KR100816960B1 (ko) * 2004-03-17 2008-03-25 화이자 인코포레이티드 2,5-디메틸-2ｈ-피라졸-3-카르복실산｛2-플루오로-5-[3-((ｅ)-2-피리딘-2-일-비닐)-1ｈ-인다졸-6-일아미노]-페닐｝-아미드의 다형성 및 무정질 형태
JP4746299B2 (ja) * 2004-07-16 2011-08-10 ジュズ インターナショナル ピーティーイー エルティーディー 金属酸化物粉末の製造方法
JP2006163651A (ja) 2004-12-03 2006-06-22 Sony Computer Entertainment Inc 表示装置、表示装置の制御方法、プログラム及びフォントデータ
US20060160863A1 (en) * 2005-01-05 2006-07-20 Agouron Pharmaceuticals, Inc. Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US8791140B2 (en) * 2007-04-05 2014-07-29 Pfizer Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds

Also Published As

Publication number Publication date
DK2625175T3 (en) 2016-02-01
CA2813329A1 (en) 2012-04-12
RS54457B1 (en) 2016-06-30
EP2625175B1 (en) 2015-11-18
EA201390275A1 (ru) 2013-07-30
CA2813329C (en) 2015-05-26
ECSP13012539A (es) 2013-06-28
NZ608482A (en) 2014-03-28
PT2625175E (pt) 2016-01-22
TW201249826A (en) 2012-12-16
HK1184147A1 (en) 2014-01-17
EA021817B1 (ru) 2015-09-30
CN103153983B (zh) 2014-11-05
ME02307B (me) 2016-06-20
KR101527661B1 (ko) 2015-06-09
CN103153983A (zh) 2013-06-12
EP2625175A1 (en) 2013-08-14
WO2012047699A1 (en) 2012-04-12
JP5940547B2 (ja) 2016-06-29
KR20130052680A (ko) 2013-05-22
HRP20151299T1 (hr) 2016-01-01
CO6710911A2 (es) 2013-07-15
AU2011312485B2 (en) 2014-09-04
MX2013003907A (es) 2013-06-03
SG188286A1 (en) 2013-04-30
JO3062B1 (ar) 2017-03-15
DOP2013000072A (es) 2013-08-15
BR112013006336A2 (pt) 2019-09-24
CL2013000884A1 (es) 2013-10-18
PE20140252A1 (es) 2014-03-12
MA34552B1 (fr) 2013-09-02
PL2625175T3 (pl) 2016-04-29
TWI418554B (zh) 2013-12-11
ES2558777T3 (es) 2016-02-08
US20120083511A1 (en) 2012-04-05
JP2013538875A (ja) 2013-10-17
AU2011312485A1 (en) 2013-03-07
UA111725C2 (uk) 2016-06-10
ZA201301560B (en) 2014-08-27
HUE026379T2 (en) 2016-06-28
IL224850A (en) 2016-09-29
AR083091A1 (es) 2013-01-30
US8530665B2 (en) 2013-09-10

Similar Documents

Publication Publication Date Title
HK1184147A1 (en) Crystalline(r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h- indazol-3-yl)vinyl)-1h-pyrazol-1-yl) ethanol and its use as fgfr inhibitor ((r)-(e)-2-(4-(2-(5-(1-(35--4-))-1h--3-) )-1h--1-) fgfr
HUS2000049I1 (hu) Kináz aktivitással rendelkezõ helyettesített imidazol származékok
HK1203959A1 (en) Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2-
RS52795B (en) VINYL INDAZOLIL UNITS
EP2346508A4 (en) HETEROCYCLIC INHIBITORS OF KINASES
ZA201001513B (en) 5-(4-(Haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
IL210174A0 (en) 4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
IL208467A0 (en) 3,4-substituted piperidine derivatives as renin inhibitors
EP2376473A4 (en) 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
HK1134670A1 (en) Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline 2-((4-(1--4-(-4-)-1h--3-)))
TN2013000142A1 (en) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
WO2011084652A3 (en) Crystalline salts of a factor xa inhibitor
BRPI0816757A2 (pt) Formas polimorfas de (s) -2- ((4-benzofuranil) carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tia zolil)carbonil) piperidina
TH115254B (th) สารประกอบไวนิลอินดาโซลอิล
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
CY1117146T1 (el) Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
ZA201007486B (en) 3,4- substituted piperidine derivatives as renin inhibitors
TH132151B (th) ((r)-(e)-2-(4-2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1 h-อินดาซอล-3- อิล)ไวนิล)-1 h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก